Eli Lilly and Company to build a manufacturing unit in North Carolina
Category: #health  By Pankaj Singh  Date: 2020-01-22
  • share
  • Twitter
  • Facebook
  • LinkedIn

Eli Lilly and Company to build a manufacturing unit in North Carolina

Global pharmaceutical firm, Eli Lilly and Company has recently revealed plans to create over 460 new jobs by investing nearly $470 million in Durham, North Carolina. Reportedly, the project would introduce a brand new state-of-the-art pharmaceutical manufacturing unit to the Research Triangle Park.

According to reliable sources, the unit would be one of the most advanced facilities that would manufacture delivery devices and parenteral (or injectable) products. Moreover, to operate this facility, Eli Lilly would generate over 400 jobs in highly skilled areas like engineers, scientists, manufacturing operations and quality professionals.

Evidently, the company owns seven manufacturing units in the U.S. that are located in New Jersey, Puerto Rico, and Indiana.

Roy Cooper, Governor, North Carolina, said that life science firms prefer to set up their businesses in North Carolina due to its exceptional quality of workforce. The region has previously drawn various global organizations and expects to maintain this upward trend in the future as it becomes a global hub for the biotechnology sector.

For the uninitiated, Lilly has had an excellent track record in discovering and developing medicines. Founded in 1876, Lilly is at the forefront of discovering a reliable solution for most debilitating and chronic health issues like cancer, diabetes, chronic pain, Alzheimer’s and autoimmune conditions.  

Recently, Eli Lilly had also made headlines when it signed a definitive agreement to acquire Dermira, Inc. for approximately $1.1 billion, valuing each share at $18.75. Dermira possesses expertise in developing innovative treatments for chronic skin disorders.

Sources close to the move state that the purchase would allow Lilly to expand its immunology pipeline by adding lebrikizumab, a novel, monoclonal, investigational antibody that treats moderate-to-severe atopic dermatitis in adults and adolescent patients that are above 12 years of age.
 

Source Credit: https://investor.lilly.com/news-releases/news-release-details/governor-cooper-announces-over-460-jobs-durham-eli-lilly-and



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

UNMC commences clinical trial of remdesivir for treating COVID-19
UNMC commences clinical trial of remdesivir for treating COVID-19
By Pankaj Singh

A controlled, randomized clinical trial to evaluate the efficacy and safety of the investigational antiviral, remdesivir, in COVID-19 patients has reportedly commenced at the University of Nebraska Medical Center (UNMC...

U.S. to pour $2.5 billion to fight potential coronavirus pandemic
U.S. to pour $2.5 billion to fight potential coronavirus pandemic
By Pankaj Singh

As the coronavirus epidemic continues to scale its way towards the West, several prominent countries across the world have started to develop novel drug solutions for fighting this disease. South Korea recently announc...

ReNeuron shares positive data from Phase 1/2a hRPC stem cell study
ReNeuron shares positive data from Phase 1/2a hRPC stem cell study
By Pankaj Singh

ReNeuron Group plc, a UK based pharmaceutical firm that specializes in cell-based therapeutics, has recently announced encouraging long-term data from its Phase 1/2a clinical study of hRPC stem cell therapy in RP (reti...